COR2ED Medical Education: In the first episode of this GI CONNECT podcast covering the lower gastrointestinal (GI) cancer highlights from ESMO 2022, Dr Jenny Seligmann, Medical Oncologist from the University of Leeds in the UK and Dr Dominik Modest, Medical Oncologist from the Charité Universitaetsmedizin, Berlin, Germany discuss a number of key oral presentations from ESMO 2022 and potential implications for clinical practice.
They start their discussion with the NICHE-2 which looked at neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer. Discussion then moves to the HIPECT4 trial which explored adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer and challenges previous perceptions of HIPEC in colorectal cancer patients. The FRESCO-2 trial is reviewed which evaluated the efficacy and safety of fruquintinib in patients with refractory metastatic CRC with results potentially supporting a new option for these patients. The experts then review two trials in patients with KRASG12C mutant CRC, the KRYSTAL-1 which used adagrasib with or without cetuximab in these patients and the CodeBreaK101 study which used sotorasib in combination with panitumumab. They discuss their opinions on the results from these studies and the implications for clinical practice.
In this episode, Dr Choo discusses some key abstracts presented during the virtual ASCO and WCGIC congresses in 2021. Dr Choo comments that despite...
We have partnered with international experts to provide rare bone disease highlights from ASBMR 2021. This is the final episode in a series of...
In this medical education podcast series, myeloma experts Dr. Karthik Ramasamy (Haematologist and Associate Professor of Haematology at the Oxford University Hospitals in London,...
